Nabla

EHR-agnostic ambient AI for clinicians: real-time ambient listening and dictation that generates clinical notes in seconds across 55+ specialties and 35 languages, expanding into clinical coding (ICD-10/HCC/E&M), clinical documentation integrity, and agentic EHR actions (orders, commands, pre-charting). Sells to health systems, medical groups, and FQHCs; by mid-2026 used across 190+ healthcare organizations handling 40M+ annual patient encounters (doubled from ~20M at the June 2025 Series C), with distribution through direct enterprise sales, Epic/Oracle Cerner integrations, the athenahealth Marketplace (30+ provider groups in year one), and the Nabla Connect embeddable module.

Stated: move from ambient documentation to a full agentic clinical platform - proactive coding agent, context-aware agent that initiates orders and EHR commands, and custom agents for nurses and inpatient settings - unified with ambient listening and dictation; 2026 plan is to scale documentation/dictation while extending into downstream workflows (advanced coding support, deeper EHR integrations, organization-specific configurations). Distribution strategy is EHR-agnostic and increasingly channel-led: Nabla Connect embeds ambient AI in any EHR, Epic/Oracle Cerner integrations, athenahealth Marketplace, plus the Navina partnership for pre-visit clinical intelligence. Inferred: differentiate on clinical evidence (NEJM AI RCT, Iowa/Denver Health/Carle studies) and frontier-research access via the AMI (Yann LeCun) relationship, aiming at FDA-certifiable autonomous clinical AI; monetize beyond burnout relief into revenue-cycle ROI (coding, CDI, documentation precision - University of Toledo case study) to justify enterprise pricing while competing as the capital-efficient, privacy-forward mid-market alternative to Abridge/Ambience.

Moderate. Peer-reviewed outcome evidence (NEJM AI trial, University of Iowa, Denver Health, Carle), deep multi-EHR workflow integrations plus an athenahealth channel, a 190+ org install base processing 40M+ encounters/year, multilingual coverage (35 languages), a distinctive privacy architecture (browser-local processing), and privileged - though contractually informal - access to AMI's world-model research. But core ambient documentation is commoditizing, switching costs are modest, Nabla holds only ~4% market share, and rivals (Abridge at $5.3B valuation, Ambience, Microsoft/Nuance) are far better capitalized. The moat depends on converting clinical trust, channel distribution, and AMI research access into stickier agentic and revenue-cycle workflows before the giants bundle them.